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Abstract
Background:  The differential diagnosis of chronic progressive multifocal asymmetric
neuropathies is challenging. Vasculitic neuropathies, multifocal forms of chronic inflammatory
demyelinating polyneuropathy, multifocal motor neuropathies, and asymmetric lower motor
neuron disorders are important considerations.
Case presentation: We report a patient with an unusually long 12-year course of nonsystemic
vasculitic neuropathy prior to the development of systemic manifestations.
Conclusion: We discuss some of the difficulties involved in the diagnosis of chronic progressive
multifocal asymmetric neuropathies.
Background
Vasculitic neuropathies may occur in the setting of sys-
temic vasculitides or in the absence of systemic features
(nonsystemic vasculitic neuropathy, NSVN).[1,2] The an-
tineutrophil cytoplasmic antibody (ANCA) associated sys-
temic vasculitides include Wegener's granulomatosis,
microscopic polyangiitis, Churg-Strauss syndrome, and
necrotizing crescentic glomerulonephritis.[3] Two distinct
ANCAs have been noted. C-ANCAs bind to the antigen
proteinase 3 and result in a diffuse cytoplasmic staining
pattern on immunofluorescence and are highly associated
with Wegener's granulomatosis, while p-ANCAs bind to
myeloperoxidase, have a perinuclear staining pattern, and
are associated with microscopic polyangiitis and Churg-
Strauss syndrome. ELISA studies available for both anti-
bodies are useful to confirm the antigenic specificity and
quantitate the ANCA when immunofluorescence shows
either this diffuse or perinuclear staining pattern.
We report a patient with an unusually long 12-year course
of vasculitic neuropathy prior to the development of sys-
temic manifestations and an eventual diagnosis of p-
ANCA microscopic polyangiitis. We discuss some of the
difficulties involved in the diagnosis of progressive multi-
focal asymmetric neuropathies.
Case Presentation
In 1989, this 47-year-old man developed mild painless
weakness of ulnar and median innervated hand and me-
dian innervated forearm muscles along with ulnar sensory
loss. Weakness gradually progressed over the following
several years. In 1992, he developed a painless sensory
deficit in the left pectoral region that never subsequently
resolved and a year later a similar deficit in the left in-
guinal region, which did resolve over months. Initial elec-
trodiagnostic studies in February 1994 (Table 1) showed
a normal right median-APB compound muscle action po-
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tential (CMAP) amplitude of 7.9 mV. F-wave responses
were absent on the right and normal on the left. The left
ulnar sensory nerve action potential (SNAP) had normal
amplitude (13 V) despite a clinical sensory disturbance
in the medial hand splitting the 4th finger. Cerebrospinal
fluid (CSF) protein was 87 mg/dl (normal < 50 mg/dl)
and there were no cells present. Serum anti-GM1 antibod-
ies were absent. Erythrocyte sedimentation rate (ESR) was
6 sec (normal < 15 sec). Chest x-ray was normal.
In March 1994, he developed acute left buttock and thigh
pain severe enough to interfere with sleep, weakness of
left hip flexion and knee extension, and parasthesias in
the anterior thigh. Needle EMG studies done acutely
showed reduced recruitment of motor unit action poten-
tials (MUAPs) without fibrillation potentials or positive
sharp waves in the left vastus medialis (VM) and L4 par-
aspinal muscles. Other leg muscles, including iliopsoas
and adductor magnus, had normal needle EMG findings.
He was treated with prednisone 60 mg every other day
and his left leg weakness and pain resolved, and the pred-
nisone was tapered over 2 months. In May 1994, he devel-
oped an acute painless right peroneal neuropathy. Needle
EMG studies showed reduced recruitment of MUAPs with
normal spontaneous activity in right tibialis anterior (TA),
peroneus longus (PL), and extensor hallucis longus
(EHL). He was treated with intravenous immunoglobulin
(IVIg) and his right foot weakness improved rapidly over
1 week. IVIg treatment was continued for 8 months until
January 1995 and by October 1995 his left proximal and
right distal leg strength was normal. In February 1996, he
developed painless left hand weakness. Needle EMG stud-
ies showed reduced recruitment of MUAPs again without
abnormal spontaneous activity in left first dorsal interos-
seous (FDI), abductor pollicis brevis (APB), and extensor
digitorum communis (EDC). He was treated with pred-
nisone for several weeks, and his strength rapidly im-
proved.
Table 1: Initial Electrodiagnostic studies in February 1994
Sensory
Nerve Amplitude (V) Velocity (m/sec)
RLR L
M e d i a n - D 2 2 21 25 9 4 7
Ulnar-D5 16 13 55 55
Dorsal ulnar 9 13 60 57
Radial 23 31 63 71
S u r a l 1 71 85 5 4 6
Motor
Nerve Amplitudes
 (mV)¶
Distal motor latency, velocities
 (msec, m/sec)§
F-wave minimum latency
 (msec)¥
R Median-APB 7.9/7.3/7.6 3.6/50/65 Absent
L Median-APB 11.0/10.6 4.0/53 27.1
R Ulnar-ADM 2.5/2.5/2.1/2.1 3.3/51/56/50 Absent
L Ulnar-ADM 7.3/6.7/5.4 3.3/61/42 29.4
R Peroneal-EDB 5.4/5.8/5.7 4.9/44/60 52.2
L Peroneal-EDB 3.5/3.1/2.9 5.2/46/45 Absent
R Tibial-AH 14.4/11.2 3.7/42 55
L Tibial-AH 11.7/9.9 4.8/51 55
¶ Amplitudes from sites as follows: median – wrist at 7 cm, elbow, axilla; ulnar – wrist at 7 cm, below elbow, above elbow, axilla; peroneal – ankle 
at 9 cm, below fibular head, above fibular head; tibial – ankle at 9 cm, popliteal fossa. § The first value is the distal motor latency and subsequent val-
ues segmental velocities. ¥ F-wave persistence and chronodispersion not recorded in the medical recordsBMC Neurology 2002, 2 http://www.biomedcentral.com/1471-2377/2/10
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For the nearly 4 year period from March 1996 – January
2000, he remained stable with moderate right median
and ulnar weakness and right ulnar sensory loss, with no
further episodes of weakness and was not treated with any
medication. He felt well and had no systemic symptoms.
In January 2000, his right hand weakness and atrophy
started to progress again, and over the next year, he be-
came unable to use the hand for many activities he was
previously capable of. He was treated for the following 2
years as follows: IVIg for 9 months, then intravenous cy-
clophosphamide 1.6 gm monthly for 6 months, and then
IVIg 1 gm/kg every 2 weeks for 9 months. During this
time, there was very gradual but definite progressive selec-
tive motor axon loss in the right hand without other clin-
ical nerve involvement. For example, the right median-
APB CMAP amplitude was 6.0 mV in March 1996, 2.1 mV
in March 2000, and 0.1 mV in May 2001, while the SNAP
amplitudes remained stable. Urinalysis in August 2001
was normal.
Treatment was stopped in December 2001 to reassess its
need. One month later he developed polyarthralgias, fe-
ver, chills, drenching night sweats, cough, nasal stuffiness,
and hemorrhagic nasal discharge. There was no current or
history of asthma. Laboratory evaluation was remarkable
for erythrocyte sedimentation rate (ESR) of 62 sec (nor-
mal < 15 sec), rheumatoid factor of 26 units (normal < 15
units), and a p-ANCA immunofluorescence pattern, with
ELISA confirmed p-ANCA antibody titer of 130 units
(normal < 2.8). There was no eosinophilia. Urinalysis
showed 2+ protein, 2+ blood, and RBC casts. Chest x-ray
showed streaky lung opacities and chest CT scan showed
multiple hazy ground glass opacities and subpleural line-
ar opacities. Corrected diffusion lung capacity (DLCO)
was 80% predicted.
Discussion
This patient had a chronic progressive multiple monone-
uropathy characterized by both acute nerve lesions, on
one occasion with significant pain, as well as a chronic
progressive nerve lesion. The CSF protein was elevated.
Systemic symptoms were absent for 12 years before their
appearance led to a diagnosis of a p-ANCA systemic vas-
culitis, which is usually associated with microscopic poly-
angiitis but maybe associated with Wegener's
granulomatosis. In a large series of patients with Wegen-
er's granulomatosis, the mean interval between onset of
the neuropathy and systemic features was 8.4 months.[4]
Although treatment with immunosuppressive agents
could have accounted for the absence of systemic symp-
toms for the last 2 years, the patient went at least 10 years
without substantial treatment likely to have masked sys-
temic symptoms, the last 4 of these without any immuno-
suppressive treatment.
Prior to the development of systemic manifestations, our
patient might best have been classified as having nonsys-
temic vasculitic neuropathy. Nonsystemic vasculitic neu-
ropathy was noted by Kissel et al. in 6 patients, painless in
1 patient, followed for up to 24 months and by Dyck et al.
in 20 patients with up to 35 years of symptoms.[1,2] In
the latter series, the median duration of peripheral nerve
disease without appearance of systemic symptoms was
11.5 years, providing evidence for the existence of an iso-
lated vasculitic neuropathy without systemic features.
However, the extent to which these patients' treatment
with immunosuppressive agents might have masked the
appearance of systemic features was not discussed. Our
patient developed systemic features for the first time 1
month after discontinuing IVIg after 2 straight years of
treatment with IVIG and cyclophosphamide. The very
long 12-year time course of our patient limited to the pe-
ripheral nerves suggested nonsystemic vasculitic neuropa-
thy, though it eventually became clear that he had a
systemic vasculitis. Nonsystemic vasculitic neuropathy
must be considered only an interim diagnosis and a high
suspicion of underlying systemic vasculitis maintained.
This view is supported by a study of 32 patients initially
diagnosed with isolated clinical vasculitic neuropathy,
though follow-up for a mean of 5 years resulted in diag-
noses of systemic vasculitis in 34%.[5]
Table 2: Temporal Profile of Right Median and Ulnar CMAP and SNAP Amplitudes
Nerve Feb 1994 March 1996 March 2000 May 2001
CMAP Amplitudes (mV)
Right Median-APB 7.9 6.0 2.1 0.1
Right Ulnar-ADM 2.5 – 2.0 Absent
SNAP Amplitudes (V)
Right Median-D2 22 19 15 28
Right Ulnar-D5 16 – 20 25BMC Neurology 2002, 2 http://www.biomedcentral.com/1471-2377/2/10
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The differential diagnosis of chronic progressive asym-
metric multifocal neuropathies remains a very challeng-
ing situation for neuromuscular specialists.
Distinguishing multifocal asymmetric forms of chronic
inflammatory demyelinating neuropathy (CIDP) from
vasculitic neuropathy can be difficult. Dyck et al. dis-
cussed the difficulties they had in excluding multifocal in-
flammatory demyelinating neuropathies in their 20
patients, particularly given that only 4 had diagnostic
nerve biopsies.[2] They questioned whether NSVN was
the same disorder as multifocal demyelinating neuropa-
thy with conduction block previously reported by Lewis et
al.,[6] and noted that 2 of their NSVN patients had con-
duction block. Indeed, since the last few years of our pa-
tient's presentation were dominated by progressive
painless atrophy and weakness of his right hand, the pa-
tient was at one point incorrectly diagnosed as having an
axonal form of multifocal motor neuropathy.[7]
We also note the value of the ANCA test in our case. A pre-
vious report noted the limited diagnostic usefulness of
ANCA testing as a screening test in patients referred for
evaluation of peripheral neuropathies due to false-posi-
tives.[8] However, in the context of a neuropathy with
characteristic features of a vasculitic neuropathy, its value
is likely higher, and a recent report and accompanying ed-
itorial recommended that ANCA testing be considered in
the evaluation of idiopathic neuropathies.[9]
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